Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

SMC approves Yescarta and Keytruda, rejects Perjeta

SMC approves Yescarta and Keytruda, rejects Perjeta

Also winning an approval is Merck/MSD’s blockbuster PD-1 drug Keytruda, for metastatic non-squamous non-small cell lung cancer. Merck/MSD’s drug was also approved through the ... In August, Keytruda was also made available as a first-line treatment

Latest news

  • Roche scores EU approval twice for Tecentriq in lung cancer Roche scores EU approval twice for Tecentriq in lung cancer

    immunotherapy Tecentriq, in both extensive-stage small cell lung cancer (ES-CLC) and non-squamous non-small cell lung cancer (NSCLC). ... It also reduced the risk of disease worsening or death. The prognosis for ES-CLC is particularly poor, with 70% of

  • Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

    This follows prior approval from cost-effective watchdog NICE, which green-lit Keytruda for use in more than 3, 000 non-small cell lung cancer (NSCLC) patients. ... Meindert Boysen, director, NICE Centre for Health Technology Evaluation. “The committee

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    In combination with chemotherapy, the anti-PD-1 therapy has been approved as a first-line medicine for those with metastatic squamous non-small cell lung cancer (NSCLC). ... Keytruda provides a foundation for the treatment of lung cancer in Europe, and

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    Celgene picked up the first of these last October when Abraxane was cleared alongside Merck &Co/MSD’s Keytruda (pembrolizumab) for frontline metastatic squamous non-small cell lung cancer. ... for a breast cancer indication – and in September, the

  • Tecentriq combo gains European NSCLC approval Tecentriq combo gains European NSCLC approval

    In combination with chemotherapy and Roche’s older cancer treatment Avastin, Tecentriq can now treat those with EGFR mutant, or ALK-positive metastatic non-squamous non-small cell lung cancer (NSCLC). ... Today’s announcement makes the combination of

More from news
Approximately 0 fully matching, plus 54 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of

  • Chinese biotech’s global ambitions Chinese biotech’s global ambitions

    has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Quick links

Infographics

Multimedia